HomeBody MapPeptidesCalculator
Catalog6 refs

CJC-1295 with DAC

Growth Hormone SecretagogueGrowth Hormone / IGF-1 AxisGrowth Hormone Releasing Hormone AnalogGrowth HormoneResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
6-8 days
Half-life
20
Uses
1-2mg weekly
Typical
Body Map
Loading 3D model…
MusclesJointsSkin
Overview

CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing compound that binds to a blood protein called albumin, extending its active life to several days. It binds GHRH receptors on pituitary somatotrophs to stimulate sustained growth hormone release, with albumin-binding DAC technology extending half-life from minutes to days. DAC covalently binds to serum albumin via a reactive maleimidopropionic acid linker, extending plasma half-life to 6-8 days. Produces sustained, non-pulsatile GH elevation (blunted GH bleed), which differs from the natural pulsatile secretion pattern. Increases mean IGF-1 levels by 1.5-3x in clinical studies.

Primary Uses
Sustained growth hormone elevation
Increasing IGF-1 levels
Promoting lipolysis and fat oxidation
Increasing lean body mass through nitrogen retention and protein synthesis
Improving body composition
Long-acting GH secretagogue research
IGF-1 elevation studies
Body-composition models
Recovery protocols
Sustained GH elevation
IGF-1 optimization
Convenient weekly dosing protocol
Fat loss enhancement
Lean mass gains
Recovery enhancement
Anti-aging
Growth hormone release
IGF-1 elevation
Growth normalization in GHRH-deficient models
Lipodystrophy (investigated, halted)
Protocol Reference
Dose
1-2mg weekly
Frequency
Once or twice weekly (e.g., Monday/Thursday for split dosing)
Half-life
6-8 days
Route
Subcutaneous injection
Evidence
Well Studied / 3 PubMed-Verified Studies / Investigational - Research compound (Preclinical/early-phase human study) (disputed)
Research References· 6
Reducing leakage power in instruction cache using WDC for embedded processors↗
DOIXin Lu, Yuzhuo FuProceedings of the ASP-DAC 2005. Asia and South Pacific Design Automation Conference, 2005.
Research Literature \- Observed in studies ↗
PubMedPMID 16352683Some use twice weekly
Invited: End-to-End Secure SoC Lifecycle Management↗
DOI2021 58th ACM/IEEE Design Automation Conference (DAC)2021Sami M, Rahman F, Farahmandi F, et al.
Research Models
humanmouse
Also in Growth Hormone Secretagogue
Growth Hormone Secretagogue
CJC-1295
Muscle growth · Anti-aging
Growth Hormone Secretagogue
CJC-1295 (Modified GRF 1-29)
Growth hormone release · Body composition improvement
Growth Hormone Secretagogue
CJC-1295/Ipamorelin
Muscle Growth · Enhanced Protein Synthesis
Growth Hormone Secretagogue
GHRP-2
Growth hormone deficiency · Cachexia
Compare